Ascendis Pharma A (ASND) EBIT (2014 - 2026)

Ascendis Pharma A has disclosed EBIT across 13 years of filings, most recently posting $29.0 million for Q1 2026.

• EBIT for Q1 2026 came in at $29.0 million, up 126.5% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.5 million (down 100.0% YoY), and the FY2025 annual result was -$158.6 million, up 46.75% from the prior year.
• EBIT came in at $29.0 million for Q1 2026 at Ascendis Pharma A, up from $11.5 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $409.3 billion in Q4 2024 to a low of -$154.2 million in Q1 2023.
• The 5-year median for EBIT is -$109.6 million (2025), against an average of $24.0 billion.
• Across the five-year window, EBIT jumped 1039121.01% in 2024 and sank 105.32% in 2025, its largest moves.
• Ascendis Pharma A's EBIT stood at -$150.4 million in 2022, then soared by 73.8% to -$39.4 million in 2023, then surged by 1039121.01% to $409.3 billion in 2024, then slumped by 100.0% to $11.5 million in 2025, then soared by 152.17% to $29.0 million in 2026.
• The last three EBIT figures came in at $29.0 million (Q1 2026), $11.5 million (Q4 2025), and $12.9 million (Q3 2025), per Business Quant data.